Literature DB >> 7053600

Combined therapy with verapamil and propranolol in chronic stable angina.

B Subramanian, M J Bowles, A B Davies, E B Raftery.   

Abstract

The comparative efficacy of verapamil (360 mg daily) and propranolol (240 mg daily) was evaluated with computerized treadmill exercise in 22 patients with chronic stable angina in a placebo-controlled double-blind crossover study with 4 weeks on each active phase. Fourteen of these patients still had angina despite active drug therapy and they were further treated with a combination of verapamil (360 mg) and propranolol (120 mg) for 4 weeks. The mean exercise time for these patients taking placebo was 4.8 +/- 0.22 minutes (mean +/- standard error of the mean) and this increased to 6.8 +/- 0.64 minutes with propranolol and 8.0 +/- 0.5 minutes with verapamil. A further increase to 10.1 +/- 0.88 minutes was observed with the combination of both drugs and seven patients became symptom-free. S-T segment criteria improved with both drugs, and combination therapy produced a further reduction in peak S-T depression. Electrocardiographic ambulatory monitoring showed no evidence of conduction defects and mean hourly heart rates were similar to those seen with propranolol alone. Left ventricular function indexes were not significantly different from those obtained with propranolol. Combination therapy with verapamil and propranolol appears to be efficacious in the treatment of selected patients with severe chronic stable angina. The patients need to be carefully monitored for adverse effects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7053600     DOI: 10.1016/0002-9149(82)90286-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

1.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 2.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

3.  The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.

Authors:  J C McCourty; J H Silas; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

4.  Antiplatelet effects of oral diltiazem, propranolol, and their combination.

Authors:  M E Ring; J J Corrigan; P E Fenster
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

Review 5.  Calcium channel blocking agents and the heart.

Authors:  J Kenny
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-26

Review 6.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 7.  Verapamil in arrhythmia.

Authors:  D M Krikler
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

8.  A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris.

Authors:  I N Findlay; K MacLeod; G Gillen; A T Elliott; T Aitchison; H J Dargie
Journal:  Br Heart J       Date:  1987-04

Review 9.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Ambulatory electrocardiographic ST segment changes in healthy volunteers.

Authors:  A A Quyyumi; C Wright; K Fox
Journal:  Br Heart J       Date:  1983-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.